TAK 044

Known as: TAK-044 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1994-2015
05101519942015

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
BACKGROUND AND AIMS Hepatic concentrations of the powerful vasoconstrictor and fibrogen endothelin 1 (ET-1) and its receptors… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
2002
2002
BACKGROUND A multifunctional mediator, endothelin (ET)-1 is implicated in the pathophysiology of liver cirrhosis. Carbon… (More)
Is this relevant?
2000
2000
OBJECT Delayed cerebral ischemia remains an important cause of death and disability in patients who have suffered subarachnoid… (More)
Is this relevant?
1999
1999
The aim of this study is to evaluate the role of non-selective endothelin blockade (TAK-044) in ischemic myocardial injury. Forty… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
1998
1998
Hepatic levels of a powerful vasoconstrictor endothelin-1 (ET-1) and its receptors increase in human and carbon tetrachloride… (More)
Is this relevant?
1997
1997
AIMS Endothelin-1 (ET-1) has been implicated in the pathophysiology of a number of cardiovascular diseases for which endothelin… (More)
Is this relevant?
1997
1997
The present study was designed to investigate if TAK-044, a novel endothelin (ET) ETA/ETB receptor antagonist, inhibits ischemia… (More)
Is this relevant?
Highly Cited
1996
Highly Cited
1996
BACKGROUND Although local inhibition of the generation or actions of endothelin-1 has been shown to cause forearm vasodilatation… (More)
Is this relevant?
1996
1996
1. We examined the effects of systemic infusion, in healthy human volunteers, of the endothelin antagonist TAK-044 on the plasma… (More)
Is this relevant?
1994
1994
Protective effects of a new endothelin (ET) receptor antagonist, TAK-044, were studied in a model of acute renal failure (ARF) in… (More)
Is this relevant?